112P - Role of EGFR mutational status in response to first-line classical chemotherapy in patients with non-small-cell lung cancer

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Personalised Medicine
Presenter Inês Franco
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors I. Franco1, A. Antunes1, S. Campainha1, S. Conde2, A.M. Barroso3
  • 1Pulmonology, Centro Hospitalar Vila Nova de Gaia/Espinho, 4430-502 - Vila Nova de Gaia/PT
  • 2Pulmonology, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia/PT
  • 3Unidade De Pneumologia Oncológica, Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E), Porto/PT

Abstract

Several studies showed that EGFR mutation is a predictor of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment response in patients with non-small-cell lung cancer (NSCLC). However, to what extent EGFR mutation status may influence the response to first-line chemotherapy regimens other than EGFR-TKI is not known. First-line treatment with EGFR-TKI was approved in Portugal in 2012. In our center, EGFR mutation analysis is performed to all NSCLC patients since 2006. The aim of this study was to evaluate the response to first-line classical chemotherapy – disease control, progression free survival (PFS) and overall survival (OS) – according to EGFR mutational status.